Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis
Neurol 97:e414-e422, Jolliffe, E.A.,et al, 2021
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
The Useless Hand of Oppenheim
Pract Neurol 17:464-468, Wiblin, L. & Guadagno, J., 2017
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Acute Idiopathic Transverse Myelitis in Children
Neurol 84:341-349,332, Deiva, K.,et al, 2015
Investigation of Leptomeningeal Enhancement in MS
Neurol 84:770-775, Eisele, P.,et al, 2015
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Intensive Care Unit Admission in Multiple Sclerosis
Neurol 82:2112-2119, Marrie, R.A.,et al, 2014
Balos Concentric Sclerosis
Lancet Neurol 13:740-746, Hardy, T.A. & Miller, D.H., 2014
Spinal Cord Lesions in Patients with Clinically Isolated Syndrome
Neurol 80:69-75, Sombekke, M.,et al, 2013
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
"Undiagnosing" Multiple Sclerosis
Neurol 78:1986-1991,1904, Solomon, A.J.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Asymptomatic Spinal Cord Lesions Predict Disease Progression in Radiologically Isolated Syndrome
Neurol 76:686-692, 680, Okuda,D.T.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Balos Concentric Sclerosis
NEJM 365:742, Wengert, O.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Acute Myeloid Leukemia in Italian Patients with Multiple Sclerosis Treated with Mitoxantrone
Neurol 77:1887-1895, Martinelli, V.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Demographic and Clinical Characteristics of Malignant Multiple Sclerosis
Neurol 76:1996-2001, Gholipour, T.,et al, 2011
Ring and Nodular Multiple Sclerosis Lesions: A Retrospective Natural History Study
Neurol 74:851-858, Davis,M.,et al, 2010
Rapid Disease Course in African Americans With Multiple Sclerosis
Neurol 75:217-223, Kister,I., et al, 2010
Longitudinal Study of Vision and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Ann Neurol 67:749-760, Talman,L.S., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
MRI Features of Benign Multiple Sclerosis: Toward a New Definition of This Disease Phenotype
Neurol 72:1693-1701, Rovaris,M.,et al, 2009
Multiple Sclerosis with Predominant, Severe Cognitive Impairment
Arch Neurol 66:1139-1143, Staff,N.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
Bal�s Disease Showing Benign Clinical Course and Co-Existence with Multiple Sclerosis-Like Lesions in Chinese
Multiple Sclerosis 14:418-424, Wang,C.,et al, 2008
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Longitudinal Follow-Up of "Benign" Multiple Sclerosis at 20 Years
Neurol 68:496-500,480, Sayao,A-L.,et al, 2007